Evaluation of preventive effects of pentoxyfylline in contrast induced nephropathy

Phase 2

• Conditions: diabetes mellitus undergoing angioplasty.; diabetes mellitus and ischemic heart disease; E11 and I2

• Registration Number: IRCT201603038307N14
• Lead Sponsor: Vice chancellor for research, Tabriz University of Medical Sciences.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Ischemic heart diseases and diabetic patients; age 18-85; undergoing of angioplasty with stent insertion; filling of consent form.

Exclusion Criteria

Elevation of CK-MB and cTnI before PCI; history of CABG during last three months; history of previous MI; renal dysfunction (creatinine above 2.5 mg/dl); unsuccessful PCI; acute MI; cardiogenic shock; dialysis; pregnancy; inability in filling and understanding of the consent form; unconsented patients; patients who want to discontinue the study at any time.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cystatin c. Timepoint: 24 hours before and after. Method of measurement: elisa kit.

Secondary Outcome Measures

Name	Time	Method
Creatinine. Timepoint: 24 hours before angioplasty and after. Method of measurement: elisa kit.